Activation of β-catenin signaling in prostate cancer by peptidyl-prolyl isomerase pin1-mediated abrogation of the androgen receptor-β-catenin interaction

Molecular and Cellular Biology

Volumn 26, Issue 3, 2006, Pages 929-939

  Chen, Shao Yong ^a   Wulf, Gerburg ^a   Zhou, Xiao Zhen ^a   Rubin, Mark A ^b   Lu, Kun Ping ^a   Balk, Steven P ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; BETA CATENIN; COMPLEMENTARY DNA; CYCLOPHILIN; GLUTATHIONE TRANSFERASE; PEPTIDYLPROLYL ISOMERASE PIN1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RNA 18S; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN LNCAP; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; BETA CATENIN; GENES, REPORTER; HUMANS; LUCIFERASES; MALE; MICE; MICE, SCID; MUTATION; NEOPLASM METASTASIS; PEPTIDYLPROLYL ISOMERASE; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; PTEN PHOSPHOHYDROLASE; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 31344433667     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.26.3.929-939.2006     Document Type: Article

References (60)

1. Amir, A. L., M. Barua, N. C. McKnight, S. Cheng, X. Yuan, and S. P. Balk. 2003. A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4. J. Biol. Chem. 278:30828-30834.
2. Ayala, G., D. Wang, G. Wulf, A. Frolov, R. Li, J. Sowadski, T. M. Wheeler, K. P. Lu, and L. Bao. 2003. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 63:6244-6251.
3. Bao, L., A. Kimzey, G. Sauter, J. M. Sowadski, K. P. Lu, and D. G. Wang. 2004. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am. J. Pathol. 164:1727-1737.
4. Barker, N., G. Huls, V. Korinek, and H. Clevers. 1999. Restricted high level expression of Tcf-4 protein in intestinal and mammary gland epithelium. Am. J. Pathol. 154:29-35.
5. Brantjes, H., J. Roose, M. van De Wetering, and H. Clevers. 2001. All Tcf HMG box transcription factors interact with Groucho-related co-repressors. Nucleic Acids Res. 29:1410-1419.
6. Brewster, S. F., S. Browne, and K. W. Brown. 1994. Somatic allelic loss at the DCC, APC, nm23-H1 and p53 tumor suppressor gene loci in human prostatic carcinoma. J. Urol. 151:1073-1077.
7. Cantley, L. C., and B. G. Neel. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 96:4240-4245.
8. Chesire, D. R., C. M. Ewing, W. R. Gage, and W. B. Isaacs. 2002. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 21:2679-2694.
9. Chesire, D. R., C. M. Ewing, J. Sauvageot, G. S. Bova, and W. B. Isaacs. 2000. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 45:323-334.
10. Chesire, D. R., and W. B. Isaacs. 2002. Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. Oncogene 21:8453-8469.
11. De la Taile, A., M. A. Rubin, M. W. Chen, F. Vacherot, S. G. De Medina, M. Burchardt, R. Buttyan, and D. Chopin. 2003. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin. Cancer Res. 9:1801-1807.
12. Deocampo, N. D., H. Huang, and D. J. Tindall. 2003. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol. 28:145-153.
13. Easwaran, V., M. Pishvaian, Salimuddin, and S. Byers. 1999. Cross-regulation of beta-catenin-LEF/TCF and retinoid signaling pathways. Curr. Biol. 9:1415-1418.
14. Gelmann, E. P. 2002. Molecular biology of the androgen receptor. J. Clin. Oncol. 20:3001-3015.
15. Gerstein, A. V., T. A. Almeida, G. Zhao, E. Chess, I. Shih, K. Buhler, K. Pienta, M. A. Rubin, R. Vessella, and N. Papadopoulos. 2002. APC/CT-NNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 34:9-16.
16. Henderson, B. R. 2000. Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover. Nat. Cell Biol. 2:653-660.
17. Hurlstone, A., and H. Clevers. 2002. T-cell factors: turn-ons and turn-offs. EMBO J. 21:2303-2311.
18. Kang, D. E., S. Soriano, X. Xia, C. G. Eberhart, B. De Strooper, H. Zheng, and E. H. Koo. 2002. Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell 110:751-762.
19. Kang, G. H., S. Lee, H. J. Lee, and K. S. Hwang. 2004. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J. Pathol. 202:233-240.
20. Korinek, V., N. Barker, P. J. Morin, D. van Wichen, R. de Weger, K. W. Kinzler, B. Vogelstein, and H. Clevers. 1997. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275:1784-1787.
21. Liu, C., Y. Li, M. Semenov, C. Ban, G. H. Baeg, Y. Tan, Z. Zhang, X. Lin, and X. He. 2002. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108:837-847.
22. Lu, K. P. 2003. Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics. Cancer Cell 4:175-180.
23. Lu, K. P., S. D. Hanes, and T. Hunter. 1996. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 380:544-547.
24. Lu, P. J., X. Z. Zhou, M. Shen, and K. P. Lu. 1999. Function of WW domains as phosphoserine- or phosphothreonine-binding modules. Science 283:1325-1328.
25. Markus, S. M., S. S. Taneja, S. K. Logan, W. Li, S. Ha, A. B. Hittelman, I. Rogatsky, and M. J. Garabedian. 2002. Identification and characterization of ART-27, a novel coactivator for the androgen receptor N terminus. Mol. Biol. Cell 13:670-682.
26. Maruyama, R., S. Toyooka, K. O. Toyooka, A. K. Virmani, S. Zochbauer-Muller, A. J. Farinas, J. D. Minna, J. McConnell, E. P. Frenkel, and A. F. Gazdar. 2002. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res. 8:514-519.
27. Masiello, D., S. Y. Chen, Y. Xu, M. C. Verhoeven, E. Choi, A. N. Hollenberg, and S. P. Balk. 2004. Recruitment of beta-catenin by wild type or mutant androgen receptors correlates with ligand stimulated growth of prostate cancer cells. Mol. Endocrinol. 18:2388-2401.
28. Morin, P. J., A. B. Sparks, V. Korinek, N. Barker, H. Clevers, B. Vogelstein, and K. W. Kinzler. 1997. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787-1790.
29. Mulholland, D. J., H. Cheng, K. Reid, P. S. Rennie, and C. C. Nelson. 2002. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J. Biol. Chem. 277:17933-17943.
30. Mulholland, D. J., J. T. Read, P. S. Rennie, M. E. Cox, and C. C. Nelson. 2003. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis. Oncogene 22:5602-5613.
31. Neufeld, K. L., F. Zhang, B. R. Cullen, and R. L. White. 2000. APC-mediated downregulation of beta-catenin activity involves nuclear sequestration and nuclear export. EMBO Rep. 1:519-523.
32. Palmer, H. G., J. M. Gonzalez-Sancho, J. Espada, M. T. Berciano, I. Puig, J. Baulida, M. Quintanilla, A. Cano, A. G. de Herreros, M. Lafarga, and A. Munoz. 2001. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J. Cell Biol. 154:369-387.
33. Pawlowski, J. E., J. R. Ertel, M. P. Allen, M. Xu, C. Butler, E. M. Wilson, and M. E. Wierman. 2002. Liganded androgen receptor interaction with betacatenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J. Biol. Chem. 277:20702-20710.
34. Persad, S., A. A. Troussard, T. R. McPhee, D. J. Mulholland, and S. Dedhar. 2001. Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J. Cell Biol. 153:1161-1174.
35. Phillips, S. M., D. G. Morton, S. J. Lee, D. M. Wallace, and J. P. Neoptolemos. 1994. Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Br. J. Urol. 73:390-395.
36. Polakis, P. 2000. Wnt signaling and cancer. Genes Dev. 14:1837-1851.
37. Ranganathan, R., K. P. Lu, T. Hunter, and J. P. Noel. 1997. Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell 89:875-886.
38. Rippmann, J. F., S. Bobbie, C. Daiber, B. Guilliard, M. Bauer, J. Birk, H. Nar, P. Garin-Chesa, W. J. Rettig, and A. Schnapp. 2000. Phosphorylation- dependent proline isomerization catalyzed by Pin1 is essential for tumor cell survival and entry into mitosis. Cell Growth Differ. 11:409-416.
39. Rosin-Arbesfeld, R., A. Cliffe, T. Brabletz, and M. Bienz. 2003. Nuclear export of the APC tumour suppressor controls beta-catenin function in transcription. EMBO J. 22:1101-1113.
40. Rosin-Arbesfeld, R., F. Townsley, and M. Bienz. 2000. The APC tumour suppressor has a nuclear export function. Nature 406:1009-1012.
41. Rubinfeld, B., I. Albert, E. Porfiri, C. Fiol, S. Munemitsu, and P. Polakis. 1996. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272:1023-1026.
42. Ryo, A., M. Nakamura, G. Wulf, Y. C. Liou, and K. P. Lu. 2001. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat. Cell Biol. 3:793-801.
43. Shah, S., A. Hecht, R. Pestell, and S. W. Byers. 2003. Trans-repression of beta-catenin activity by nuclear receptors. J. Biol. Chem. 278:48137-48145.
44. Sharma, M., W. W. Chuang, and Z. Sun. 2002. Phosphatidylinositol 3-kinase/ Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J. Biol. Chem. 277:30935-30941.
45. Shen, M., P. T. Stukenberg, M. W. Kirschner, and K. P. Lu. 1998. The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosisspecific phosphoproteins. Genes Dev. 12:706-720.
46. Song, L. N., R. Herrell, S. Byers, S. Shah, E. M. Wilson, and E. P. Gelmann. 2003. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol. Cell. Biol. 23:1674-1687.
47. Tetsu, O., and F. McCormick. 1999. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426.
48. Truica, C. I., S. Byers, and E. P. Gelmann. 2000. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 60:4709-4713.
49. van de Wetering, M., E. Sancho, C. Verweij, W. de Lau, I. Oving, A. Hurlstone, K. van der Horn, E. Batlle, D. Coudreuse, A. P. Haramis, M. Tjon-Pon-Fong, P. Moerer, M. van den Born, G. Soete, S. Pals, M. Eilers, R. Medema, and H. Clevers. 2002. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111:241-250.
50. Vivanco, I., and C. L. Sawyers. 2002. The phosphatidylmositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2:489-501.
51. Voeller, H. J., C. I. Truica, and E. P. Gelmann. 1998. Beta-catenin mutations in human prostate cancer. Cancer Res. 58:2520-2523.
52. Wong, N. A., and M. Pignatelli. 2002. Beta-catenin-a linchpin in colorectal carcinogenesis? Am. J. Pathol. 160:389-401.
53. Wulf, G., A. Ryo, Y. C. Liou, and K. P. Lu. 2003. The prolyl isomerase Pin1 in breast development and cancer. Breast Cancer Res. 5:76-82.
54. Wulf, G. M., Y. C. Liou, A. Ryo, S. W. Lee, and K. P. Lu. 2002. Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J. Biol. Chem. 277:47976-47979.
55. Wulf, G. M., A. Ryo, G. G. Wulf, S. W. Lee, T. Niu, V. Petkova, and K. P. Lu. 2001. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 20:3459-3472.
56. Yaffe, M. B., M. Schutkowski, M. Shen, X. Z. Zhou, P. T. Stukenberg, J. U. Rahfeld, J. Xu, J. Kuang, M. W. Kirschner, G. Fischer, L. C. Cantley, and K. P. Lu. 1997. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 278:1957-1960.
57. Yang, F., X. Li, M. Sharma, C. Y. Sasaki, D. L. Longo, B. Lim, and Z. Sun. 2002. Linking beta-catenin to androgen-signaling pathway. J. Biol. Chem. 277:11336-11344.
58. Yegnasubramanian, S., J. Kowalski, M. L. Gonzalgo, M. Zahurak, S. Piantadosi, P. C. Walsh, G. S. Bova, A. M. De Marzo, W. B. Isaacs, and W. G. Nelson. 2004. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 64:1975-1986.
59. Yu, X., P. Li, R. G. Roeder, and Z. Wang. 2001. Inhibition of androgen receptor-mediated transcription by aminoterminal enhancer of split. Mol. Cell. Biol. 21:4614-4625.
60. Zhou, X. Z., O. Kops, A. Werner, P. J. Lu, M. Shen, G. Stoller, G. Kullertz, M. Stark, G. Fischer, and K. P. Lu. 2000. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol. Cell 6:873-883.